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Introduction
Mammary luminal and basal epithelial cells originate from multipotent progenitors in the embryo(1-2) and expansion and maintenance of these cells in adults are ensured by unipotent luminal stem cells (LSCs) and basal stem cells (BSCs), respectively (1, 3) . Cancer stem cells (CSCs) are a subpopulation of cancer cells that shares characteristics with stem cells such as self-renewal ability and mutipotency. CSCs could generate daughter cells, thus contributing to tumor growth, and are associated with radio-and chemo-resistance, metastasis, and poor prognosis (4) . Germline mutations in the tumor suppressor BRCA1 contribute to about half of familial breast cancer cases and increase the risk of developing basal-like breast tumors with high metastasis and poor prognosis. Basal-like tumors developed in BRCA1 mutation carriers were thought to originate from either mammary stem cells or basal progenitors (5) (6) . Recently, we and others discovered that aberrant LSCs, not basal stem cells/progenitors, are likely the origin of basal-like tumors developed in patients harboring BRCA1 mutations as well as in germline Brca1 +/-mutant mice (7) (8) (9) (10) . Furthermore, breast cancer stem cells are enriched in human BRCA1 mutant breast cancers (11) (12) . However, whether BRCA1 functions in LSCs to maintain their unipotency, and whether and how BRCA1 controls breast cancer stem cells and basal-like tumors in vivo, remain elusive.
EMT plays an important role in intratumoral heterogeneity, breast basal-like tumor development, and generation of breast epithelial and cancer cells with stem cell-like characteristics, directly linking EMT with the gain of stem cell properties (13) (14) . A set of transcription factors including TWIST1/2, SNAIL, SLUG, ZEB1/2, and FOXC1/2 was identified as EMT-inducing transcription factors (EMT-TFs). Among these, TWIST1 (TWIST) is a master regulator of EMT and plays an essential role in tumor metastasis (15) .
Research.
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Author Manuscript Published OnlineFirst on September 19, 2014 ; DOI: 10.1158/0008-5472.CAN- p18 is a member of the INK4 family of cell cycle inhibitors that inhibits CDK4/6 and, when activated by D-type cyclins, phosphorylates and functionally inactivates RB1, p107, and p130. p18 expression is significantly lower in human breast cancers than normal breast ((16-17) and Bai unpublished data). RB1 has been identified as a major target for genomic disruption in basal-like breast cancers of BRCA1 mutation carriers (18) , and loss of both RB1 and BRCA1 is, indeed, a feature of basal-like human breast cancers (17, 19) . Deletion of Rb alone in mouse mammary epithelia does not induce tumors (20) and deletion of both Rb and p107 results in luminal type tumors (19) , suggesting a role of the Rb pathway in controlling luminal tumorigenesis. Interestingly, deletion of p18, which functionally inactivates the Rb pathway, stimulates mammary LSC proliferation and results in luminal type tumors (16) as well as rescues the premature senescence caused by Brca1 deficiency. Thus p18;Brca1 double mutant mice provide a unique mouse model with a genetically intact p53 pathway and functionally inactivated Rb pathway (10) to study the role of Brca1 in breast tumor suppression. .
In this report, we used Brca1 germline and conditional mutant mice as well as human breast cancer cells and samples to determine the function and mechanism of Brca1 in suppressing EMT and basal-like tumors.
Research. 
Materials and Methods

Mice, histopathology, and immunohistochemistry
The generation of p18 and Brca1 germline mutant mice have been described previously (10, 16) .
Brca1
f/f and Tg(MMTV-Cre)4Mam mice were obtained from the NCI Mouse Repository and JAX lab, respectively (21) (22) . All animal procedures were approved by the Institutional Animal Care
and Use Committee at the University of North Carolina and University of Miami. Histopathology and immunohistochemistry were performed as described previously (10, 16 
Mammary cell preparation, FACS analysis, cell sorting, mammosphere assay, colonyformation assay, cell lines, transfection, and lentiviral infection
Mammary glands were dissected from female mice at the indicated ages and the tissue was processed as previously described (10, 16, (23) (24) . MCF-7, T47D (ATCC), SUM149 (Dr.
Sendurai Mani, University of Texas, Houston, TX), and HCC1937 (Dr. Jennifer Hu, University of Miami, Miami, FL) cells were tested and authenticated (10, (25) (26) . For ectopic expression of BRCA1, HCC1937 cells were transfected with pcDNA3-empty or pcDNA3-BRCA1 with FuGene.
For BRCA1 knockdown, pGIPZ-empty (Sh-Ctrl) and pGIPZ-shBRCA1 (Sh-BRCA1) lentiviral vectors were purchased from Open Biosystems.
Xenograft models of breast cancer
T47D and MCF-7 Sh-Ctrl and Sh-BRCA1 cells were suspended in a 50% solution of Matrigel (BD), then inoculated into the left and right inguinal mammary fat pads of 6-week-old female NSG mice (Jackson Laboratory), respectively. 18 weeks after transplantation, animals were
Research. euthanized and mammary tumors were dissected for analyses. No estrogen was administered to animals during the course of the study.
Western blot, Q-RT-PCR, and ChIP assay
Western blot, Q-RT-PCR, and ChIP assay were carried out as previously described (10, 16, 27) .
Primary antibodies used for Western blot are as follows: Brca1, Gata3 (Santa Cruz), E-cadherin, Fibronectin, Tubulin-(DM1A, NeoMarkers), Actin (ACTN05, NeoMarkers). Anti-BRCA1 antibody (D-9, Santa Cruz) or control mouse IgG were used to precipitate chromatin associated with BRCA1. Q-PCR was performed to determine the relative abundance of target DNA.
Specific primers for the analysis of BRCA1 binding to TWIST are available upon request.
Human tumor samples
Formalin fixed paraffin-embedded (FFPE) human breast cancer samples lacking patientidentifying information were obtained from the Tissue Bank Core Facility at the University of Miami. All samples obtained were non-treated invasive breast cancers with known ER status.
Regions from tumor samples were microdissected and only samples with a consistent tumor cell content >75% of tissues were used for RNA extraction. The expression of BRCA1 was determined by Q-RT-PCR.
Patients and gene-expression data sets
The UNC337 human breast cancer dataset(28) with 337 breast cancer samples and the MetaBric dataset(29) with 2,000 samples were analyzed. We compared gene expression versus six breast cancer subtypes using two-way analysis of variance (ANOVA).
Research. Table 1 ). This observation suggests that heterozygous germline mutation of Brca1 activates EMT in mammary tumor progression.
Consistently, p18
-/-;Brca1 +/-tumor cells that were positive for Ck5 expressed very low levels of Cdh1 (Suppl. Fig. 1A ) and the majority of Fn positive cells co-expressed Ck5 (Fig. 1B 
Germline mutation of Brca1 activates EMT-TFs in mammary and tumor development
We then determined the expression of EMT-TFs and observed that 77% (n=13, >one year of age) of p18 
We then examined p18 ;Brca1 f/f ;MC mice were also highly heterogenous, poorly differentiated, and more aggressive than those developed in p18 -/-mice (Fig. 3, Fig. 1 , Suppl. ;MC tumor cells were spindle-shaped and were positive for Twist and Fn (Fig. 3A, B) , and more than 40% of the tumor cells were positive for Ck5 and negative for Cdh1 or Ck8 (Fig. 3C, D and Balb/c mixed backgrounds, unlike p18 -/-;Brca1 +/-mice in pure Balb/c background, these data also suggest that the role of Brca1 controlling basal-like tumorigenesis and EMT is independent of genetic background.
BRCA1 suppresses TWIST transcription and EMT
We screened a panel of human breast cancer cell lines and found that MCF7 and T47D cells expressed higher CDH1 and GATA3 and lower VIM and EMT-TFs than SUM149 and HCC1937 cells (Suppl. Fig. 6 ), confirming that MCF7 and T47D cells are luminal/epithelial-like and SUM149 and HCC1937 cells are basal/mesenchymal-like cancer cells in our culture system (35) .
Transfection of WT BRCA1 into HCC1937 (BRCA1 mutant, transcriptionally null) cells resulted in increase of CDH1 and decrease of VIM and FN, indicating that BRCA1 suppresses EMT.
Importantly, ectopic expression of BRCA1 significantly repressed TWIST by more than 50% compared to control, moderately repressed FOXC2, but hardly repressed other EMT-TFs (Fig.   4A) . A similar inhibitory effect on TWIST and FOXC2 expression was also detected in 293T cells transfected with BRCA1 (Suppl. Fig. 7 ). Since the ability of BRCA1 in regulating transcription controls normal differentiation and suppresses tumor development(36-37), we determined whether BRCA1 is recruited to the TWIST promoter. A previous study demonstrated that GATA3 recruits BRCA1 to its binding sites in the FOXC1/2 promoters to repress their transcription (27) . We performed bioinformatic analysis of the TWIST gene promoter and found that there exists, at the least, six putative GATA3 binding sites on the TWIST promoter (Fig. 4B ),
on January 8, 2018. © 2014 American Association for Cancer cancerres.aacrjournals.org Downloaded from which are conserved in both human and mouse (data not shown). We then performed a ChIP assay and found that one of five amplicons that contained two GATA3 sites was specifically enriched in the immunoprecipitation of BRCA1 in HCC1937 cells transfected with WT BRCA1 compared to control (P5 in Fig. 4C ). In sum, these results suggest that BRCA1 specifically binds to the TWIST promoter and negatively regulates its transcription.
To confirm the role of Brca1 in the suppression of Twist and tumor development in situ, primary mammary tumors derived from p18 -/-;Brca1 +/-mice were immunostained with antibodies against Brca1 and Twist. We found that tumor cells positive for Brca1 expressed very low or no Twist whereas Brca1 mutant tumor cells expressed high levels of Twist, most of which were spindle-shaped basal-like cells (Fig. 4D) , demonstrating that Brca1 inhibits Twist and EMT in mammary tumor development and progression.
Knockdown of BRCA1 in activates TWIST and EMT with enhanced tumor formation potential
We knocked down BRCA1 in two human luminal cancer cell lines, MCF7 and T47D, using BRCA1 shRNA targeting 3 different sequences (Fig. 5A , and data not shown), and transplanted these cells into the mammary fat pads of NSG mice. We found that mammary tumors from T47D-Sh-BRCA1 cells were palpable in eight weeks whereas tumors formed from T47D-Sh-Ctrl.
cells were undetectable at this stage (data not shown). Eighteen weeks after transplantation, T47D-Sh-BRCA1 tumors were significantly bigger than T47D-Sh-Ctrl. tumors (Fig. 5B, C) . heterogenous with an abundance of large and poorly differentiated cells (Fig. 5D) , suggesting that KD of BRCA1 induced the dedifferentiation of luminal tumor cells. IHC analysis indicated that most cells in T47D-Sh-BRCA1 tumors expressed very faint or no CDH1 and ERα but high levels of TWIST, VIM, and FN in comparison to T47D-Sh-Ctrl. tumors (Fig. 5E-G, Suppl. Fig. 8 (28) . Of these subtypes of breast cancer, the CL subtype is characterized by the low to absent expression of luminal differentiation markers and high enrichment for EMT markers and cancer stem cell-like features. Clinically, the majority of CL tumors are poor prognosis triple negative (ER-, PR-, and HER2-) invasive carcinomas with high frequencies of metaplastic and medullary differentiation (28, (38) (39) . To determine whether our mouse genetic analysis models human breast cancers, we queried the expression of BRCA1 and EMT-TFs in the UNC337 breast cancer patient sample sets (28) . We found that expression of BRCA1 and EMT-TFs were highly correlated with breast tumor intrinsic subtypes ( Figure 6A ). Specifically, the mRNA level of BRCA1 was low while that of EMT-TFs -TWIST, SNAIL, and SLUG in particular -was high in the CL subtype. Pearson correlation analysis revealed an inverse correlation between BRCA1
with TWIST mRNA levels, but not with SNAIL, SLUG, and FOXC1 (Fig. 6B) . We performed closely associated with that of CK5 and was inversely correlated with the mRNA level of BRCA1 (Fig. 6C, D) . Furthermore, all TWIST positive tumors were highly heterogeneous, poorly differentiated, and showed typical morphological EMT features, evidenced by the various degrees of whorls and clusters of spindle-shaped cells within these tumors. Together, these clinical findings, consistent with our results in mice, further confirm that BRCA1 suppresses TWIST and EMT in breast basal-like cancer development and progression.
Discussion
In this paper, we confirm our previous finding that heterozygous mutation of Brca1 in p18 deficient mice transforms luminal tumors into basal-like tumors (10) Foxc1 and Twist (9) . Furthermore, Brca1 was found to bind to the promoters of FOXC1 and FOXC2 and repress their transcription (27) . These findings support the function of Brca1 in suppressing EMT-TFs, however, all of these data were derived from either BRCA1 mutation carriers with unknown patient genetic background, Brca1 mutant mice in p53 deficient background, or breast cancer cell lines (8) (9) 27 ). The present study shows, for the first time in mRNA is moderately, suppressed by BRCA1 (Fig. 4) . Further supporting these results, our data 
